More action is in store in the competitive diabetes segment in India, with Glenmark Pharmaceuticals Ltd. now readying a fixed-dose combination (FDC) of the sodium glucose co-transporter-2 (SGLT2) inhibitor remogliflozin and the dipeptidyl peptidase-4 (DPP-4) inhibitor teneligliptin.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?